Herein, we report the kinetics of the anti-tumor immune responses in this patient who received a total of 9 re-infusions of ex vivo TKD/IL-2-activated, autologous leukapheresis products over a 12-month period and the clinical follow-up for 1 year. The gene discussed is IL2; the disease is neoplasm.